To include your compound in the COVID-19 Resource Center, submit it here.

Eureka reports Phase I response data for anti-CD19 T cell therapy in lymphoma

Eureka Therapeutics Inc. (Emeryville, Calif.) reported preliminary data from 17 evaluable patients with CD19-positive, relapsed and

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE